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A review on experimental and clinical genetic
associations studies on fear conditioning, extinction
and cognitive-behavioral treatment
TB Lonsdorf and R Kalisch
Fearconditioningandextinctionrepresentbasicformsofassociativelearningwithconsiderableclinicalrelevanceandhavebeen
implicated in the pathogenesis of anxiety disorders. There is considerable inter-individual variation in the ability to acquire and
extinguishconditionedfearreactionsandthestudyofgeneticvariantshasrecentlybecomeafocusofresearch.Inthisreview,we
give an overview of the existing genetic association studies on human fear conditioning and extinction in healthy individuals and
ofrelatedstudiesoncognitive-behavioraltreatment(CBT)andexposure,aswellaspathologydevelopmentaftertrauma.Variation
in the serotonin transporter (5HTT) and the catechol-o-methyltransferase (COMT) genes has consistently been associated with
effects inpre-clinical and clinical studies. Interesting newﬁndings, which howeverrequirefurther replication, havebeenreported
for genetic variation in the dopamine transporter (DAT1) and the pituitary adenylate cyclase 1 receptor (ADCYAP1R1) genes,
whereas the current picture is inconsistent for variation in the brain-derived neurotrophic factor (BDNF) gene. We end with a
discussion of the ﬁndings and their limitations, as well as future directions that we hope will aid the ﬁeld to develop further.
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Introduction
Learning to predict danger from previous experience is critical
to an organism’s survival. In fear conditioning, an environ-
mental stimulus (conditioned stimulus, CS) comes to
predict a naturally aversive stimulus (unconditioned stimulus,
UCS) and thereby to induce a conditioned fear response
(CR).
1 After conditioning has occurred, the repeated
presentation of the CS in the absence of UCS (exposure)
leads to a gradual weakening of the CR, a process referred
to as extinction.
Fear conditioning and extinction represent basic forms of
associative learning with considerable clinical relevance and
have been implicated in the pathogenesis of anxiety dis-
orders.
2 Deﬁcits in the extinction of learned fear associations
have been observed in patients suffering from anxiety
disorders like post-traumatic stress disorder (PTSD), phobias
andpanicdisorder(PD).
3,4Further,extinctionhasinspiredthe
clinical use of exposure to fear stimuli
5 in cognitive-behavioral
therapy (CBT), which is used to treat many forms of
pathological anxiety.
6,7 CBT represents a learning process
leading to symptom relief and long-term changes in behavior
that have measurable correlates in neural activation patterns,
synaptic connectivity and gene expression patterns.
8,9
Understanding the molecular pathways that mediate con-
ditioning and extinction might therefore make an important
contributiontothestudyofanxietypathophysiology,resilience
and treatment mechanisms, and open up new perspectives
for pharmacological interventions. One promising, although
by far not the only, strategy to identify molecular pathways in
humans is genetic association studies.
Genetic association studies optimally investigate simple
behavioral paradigms with sufﬁcient inter-individual variability
and clear heritability that elicit robust behavioral responses,
which are easy to measure and quantify and rely on a well-
deﬁned underlying neural circuitry. Fear conditioning and
extinction fulﬁll these criteria.
First, both human
10,11 and animal studies
12 show that there
is considerable inter-individual variability in the ability to
acquire and extinguish conditioned fear as well as in proﬁting
from CBT, and that genetic factors represent a signiﬁcant
source of this variation. Speciﬁcally, one-third of the variance
inhumanfearconditioning
10andinthevulnerabilityforanxiety
disorders
13 is attributed to genetic factors.
Second, conditioned fear can be easily and reliably
measured using, for example, skin conductance responses
(SCRs) and/or fear potentiated startle (FPS) responses (see
Table 1 for explanation of technical terms). Importantly, twin
studies have proven the reliability of both SCRs
10 and FPS
11
for heritability studies.
Third, the neural network underlying fear conditioning and
extinction has been studied intensively in both animals
14,15
and humans.
16 A well-delineated neural network is not only
advantageous for genetic imaging studies,but may also guide
selection of candidate genes.
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molecular pathways, covering conditioning and extinction in
healthy individuals, CBT and exposure outcome in clinical
populations, as well as PTSD development after trauma. We
try to propose mechanistic interpretations, critically discuss
limitations and pitfalls, and show up interesting new directions
for future research.
Serotonin
Although the serotonin (5-HT) system presents with a multi-
tude of promisingcandidate genes, only polymorphisms inthe
serotonin transporter (5-HTT) gene, which is responsible for
presynaptic 5-HT reuptake (for a review, see ref. 17), and the
monoamine oxidase A (MAO-A) gene, which degrades 5-HT
(for a review, see ref. 18), have been studied with respect to
fear conditioning and extinction processes.
5-HTTLPR. 5-HTT presents with a 43bp insertion/deletion
polymorphism in its promoter region, which is referred to as
5-HTT linked polymorphic region (5-HTTLPR) and most
commonly comprises a short (s) and a long (l) variant. The
s-allele is associated with B50% reduced transcriptional
activity in vitro,
19 but human in vivo or post-mortem studies
failed to reveal consistent functional effects,
20–22 probably
because the polymorphism exerts its effect during early
neurodevelopment (for example, ref. 23).
The G-allele of a functional A/G single-nucleotide poly-
morphism (SNP, rs25531) upstream of the 5-HTTLPR
24
is almost always in phase with the 5-HTTLPR l-allele
25
and is associated with reduced 5-HTT transcriptional efﬁ-
cacy.
24,26 5-HTTLPR and rs25531 are often combined
as a functional mini-haplotype (‘tri-allelic 5-HTTLPR’). The
l-allele of the 5-HTTLPR is thereby further subdivided into LA
and LG. Functionally, the LG-allele is equivalent to the low
expressing 5-HTTLPR s-allele,
26 and grouping of individuals
based on the triallelic 5-HTTLPR is based on inferred 5-HTT
expression levels.
26
Three experimental and ﬁve clinical studies have to
date investigated an association of the bi- and/or triallelic
5-HTTLPR with fear conditioning- and/or extinction-related
processes.
Garpenstrand and co-workers
27 selected 20 good and 20
bad performers from a cohort of 346 fear-conditioned
subjects, on the basis of their SCR discrimination, during
conditioning, between a CS paired with the UCS (CSþ),
and a control stimulus never paired with the UCS (CS )
(seeTables2and3 fordetailsondesignandsample). Testing
for CSþ/CS  discrimination is an appropriate means to
control for general sensitization and stimulus responsivity
effects. The authors observed an over-representation of the
5-HTTLPR s-allele in the good performers and, accordingly,
signiﬁcantly more SCR discrimination (CSþ4CS )i n
s-allele carriers than in non-carriers. This effect was
maintained during (immediate) extinction on a descriptive
level (P¼0.11).
Lonsdorf and co-workers
28 replicated and extended the
above ﬁndings in a sample of 48 volunteers, partly selected a
priori for their 5-HTTLPR and COMTval158met (see below)
genotypes. Eyeblink startle responses were induced by
presenting auditory (startle probe) probes during both types
of CSs and during the inter-trial interval (ITI, see Table 1
for explanations of technical terms). S-carriers displayed
signiﬁcantly more FPS CSþ potentiation (CSþ4ITI) during
acquisition than non-carriers, in the absence of signiﬁcant
differences in CSþ/CS  discrimination, CS  potentiation
(CS 4ITI) or ITI raw startle (untransformed ITI scores
elicited during the ITI). In addition, while s-carriers showed
the expected conditioning-related effects (signiﬁcant CSþ
and CS  potentiation, CSþ/CS  discrimination), these
effects were absent in non-carriers. During the 24h delayed
extinction phase, s-carriers again showed signiﬁcantly more
CSþ potentiation, but also less CS  inhibition (CS oITI, an
effect that is taken to reﬂect the learned safety of the CS ), in
the absence of group differences in CSþ/CS  discrimination
or ITI raw startle. However, using SCR, no learning-related
groupdifferenceswereobserved,whetherduringconditioning
or extinction (see below for a discussion of the different
measurements).
Finally, Crisan and co-workers
29 reported an association
between the 5-HTTLPR s-allele and enhanced observational
fear learning
30 in 32 participants. In this paradigm, s-carriers
displayed marginally higher SCRs when observing a model
(that is, another person) being presented with the CSþ or the
UCS, but not when the model was presented with the CS .
During subsequent testing, s-carriers displayed signiﬁcantly
higher SCRs to CSþs, but not to CS s, presented to
Table 1 Explanation of technical terms and abbreviations
Term Explanation
Fear potentiated startle
(FPS)
Augmentation of the startle reﬂex by a
fearful state, for example, induced by
a certain stimulus
Dark-enhanced startle Augmentation of the startle reﬂex by
darkness
Skin conductance response
(SCR)
The alteration in the electrical
resistance of the skin associated with
psychological or physiological arousal
Unconditioned stimulus
(UCS)
In experimental human studies often
an aversive electrotactile stimulation
or an air puff to the eye
CS+ Stimulus that predicts the UCS
CS  Stimulus that does not predict the
UCS
CS+ potentiation Augmentationofareaction(e.g.,FPS)
elicited by/during the CS+ as
compared to a reaction elicited by/
during the ITI
CS  potentiation Augmentationofareaction(e.g.,FPS)
elicited by/during the CS  as
compared to a reaction elicited by/
during the ITI
CS+/CS  discrimination Augmentationofareaction(e.g.,FPS)
elicited by/during the CS+ as
compared to a reaction elicited by/
during the CS 
Inter-trial interval (ITI) Time between two stimulus
presentations; here: time between
two CS’s
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Translational Psychiatrythemselves in the absence of the UCS. Group differences
were reported in analyses that tested SCRs to the CSþ and
the CS  separately; however, no statistics on CSþ/CS 
discrimination was given.
In sum, three experimental studies reported facilitated
fear learning in 5-HTTLPR s-allele carriers in at least one
psychophysiological modality (SCR or FPS), an effect that
appears to carry over into subsequent extinction. Importantly,
as far as reported, groups did not differ in the intensity levels
chosen for UCS presentations,
27,28 in SCRs to received
UCSs, or in ITI raw startle (ref. 28).
PTSD is the prototypical anxiety disorder where fear
conditioningmakesanunquestionablecontributiontodisease
aetiology (for example, see ref. 31). If 5-HTTLPR genotype
affects fear conditioning propensity, it should also be
associated with PTSD vulnerability. Three epidemiological
studies support this claim and thus underscore the transla-
tional potential of conditioning genetics.
In a sample of hurricane victims (N¼589), PTSD risk was
enhanced in individuals carrying the s/s genotype if they also
received low social support
32 or if they also lived in high-risk
environments (characterized, for example, by crime or
unemployment).
33 By contrast, s/s-carriers had a lower risk
to develop PTSD in low-risk environments.
33 However, both
analyses were limited by the very low number of individuals
with a current PTSD diagnosis (N¼19, whereof n¼4
5-HTTLPR s/s-carriers). Finally in a study in 424 unrelated
refugees of the Rwandan civil war, Kolassa and co-workers
found an enhanced risk for lifetime PTSD in s/s-carriers
irrespective of trauma load (as assessed 12–13 years later
by counting the number of different traumatic event
types experienced/witnessed), whereas l-carriers (s/l and l/l)
exhibited the expected dose–response relationship between
trauma load and lifetime risk.
34 At very high traumatic load
however (415 events), no differences in lifetime risk were
found between the genotype groups, suggesting that the
inﬂuence of genetics decreases with increasing trauma load.
Hence, the clinical data are in agreement with the idea that
low 5-HTT expression is associated with facilitated and more
persistent fear conditioning, whereas high 5-HTT expression
is associated with abnormal resistance to fear conditioning.
However, it remains elusive if the apparent persistence of fear
simply reﬂects a carryover of stronger fear into later exposure
or perhaps deﬁcits in the corrective safety learning that
characterizes extinction. Unfortunately, the preclinical studies
did not assess rates of extinction as one means to quantify
learning.However,providedoneacceptstheideaofextinction
learning as the major active ingredient to CBT, two recent
therapy studies permit interesting conclusions.
Bryant and co-workers
35 investigated 42 unmedicated
PTSD patients who were provided with weekly 90-min
individual CBT sessions for 8 weeks. CBT reduced symptoms
equally inboth groups,and therewere nosigniﬁcantgenotype
group differences in symptom scores before and immediately
after treatment, signiﬁcantly more individuals with inferred low
5-HTT expression (s- and LG -carriers) met PTSD diagnosis
6 months after treatment and also reported more symptoms
as compared to non s- and non-LG -carriers (LA/LA). Lonsdorf
and co-workers
36,37 reported a similar ﬁnding of persis-
tently higher symptom scores in s- and LG-carriers in 69 PD
patients treated with weekly CBT sessions (regular group or
internet-based CBT) for 10 weeks. In contrast to the study by
Bryant and co-workers
35 group differences in symptom
scores reached signiﬁcance also at pre- and post-treatment.
Because in both studies, acute symptom reduction thought
CBT succeeded equally well in both genotype groups
(excluding deﬁcits in corrective safety learning in s- and
LG-carriers), the explanation of the group differences of the
6-month follow-up scores most likely be sought in the
persistence and durability of the fear memories generated
during trauma.
It should be noted that there are currently no twin studies
showing heritability of CBT. Nevertheless, if taken together,
existing data on the bi- and triallelic 5-HTTLPR genotype yield
an impressively consistent picture across preclinical–experi-
mental, epidemiological and therapy studies, making
5-HTTLPR a prime example for successful translation of
biochemical and molecular–genetic ﬁndings into human
pathophysiological research.
MAO-A VNTR. The human MAO-A gene contains an
untranslated variable number of tandem repeat region
(MAO-A uVNTR)
38 that yields six different alleles that vary
in transcriptional efﬁciency (2Ro3Ro3.5R¼4R). Functional
data are inconsistent for the 5R
38,39 and absent for the
6R-allele (for a review, see ref. 23).
Garpenstand and co-workers
27 found no differences in
SCR conditioning and extinction between individuals with
putatively high (3.5R/4R) or low (3R/5R) MAO-A expression
levels in an additional analysis of the sample described
above.
Dopamine
Like 5-HT, the dopamine (DA) system yields a multitude of
promising candidate genes, and studies on fear conditioning,
extinction, CBT and PTSD development after trauma
have investigated associations with polymorphisms in
the catechol-O-methyltransferase (COMT), DA transporter
(DAT1), D2 (DRD2) and D4 (DRD4) receptor genes.
COMT val158met (rs4680). COMT degrades extracellular
DA (for a review, see ref. 40) and is of primary importance
in the prefrontal cortex, but less so in striatal areas.
41
The COMT gene harbors a functional A/G SNP, leading to
the substitution of the amino-acid valine by methionine at
codon 158 (COMTval158met). Homozygosity for the met
allele leads to four times reduced enzymatic activity
compared to homozygosity for the val-allele,
42 and thereby
affects effectiveness of DA degradation by COMT and the
availability of synaptic DA (higher in met-carriers).
43
Two experimental and three clinical studies have to date
investigated an association of COMTval158met with fear
conditioning and/or extinction processes.
In a sample of 48 volunteers, partly selected a priori for
COMTval158met genotype (and 5-HTTLPR, see above
28)
Lonsdorf and co-workers
37 reported no association of
COMTval158met genotype with FPS and SCR conditioning.
However, during 24-h delayed extinction, met/met-carriers
showed signiﬁcantly enhanced CSþ potentiation compared
Genetics of fear conditioning and extinction
TB Lonsdorf and R Kalisch
6
Translational Psychiatryto val-carriers, suggesting resistance to extinction. No group
differences in CSþ/CS  discrimination, CS  potentiation,
raw ITI startle or SCRs were observed. As a limitation of this
study, the low number of homozygous met-carriers has to be
mentioned.
In a subsequent clinical study, the same group
37 also
investigated the efﬁcacy of exposure-based CBT in 69 PD
patients (see also above). Supporting the notion of extinction
resistance, met/met-carriers seemed to beneﬁt less from
exposure-based treatment modules (vs cognitive modules)
than val-carriers. Hence, COMT met/met-carriers do not
seem to differ from val-carriers in their conditionability, but in
their ability to use corrective experience for fear reduction,
which is in line with the met-allele being associated
with emotional perseveration, reduced cognitive ﬂexibility,
but enhanced stability.
44,45
Raczka and co-workers
46 investigated 69 healthy male
participants selected a priori based on their COMTval158met
genotype (and a DAT1 VNTR, see below) in an experiment
involving conditioning, immediate extinction and immediate
reconditioning. Like in the ﬁrst COMT study,
26 COMT
genotype had no measurable effect on indices of conditioning
(SCR as well as subjective fear ratings intermittently provided
throughout the experiment). However, there was also no
association with extinction learning in SCR and fear ratings,
aswellasinacomputationalanalysisoffearratingtimeseries
by virtue of a formal reinforcement learning model. The latter
provides a possibility to estimate extinction learning rates and
thus to gain a more ﬁne-grained picture of the associative
processes occurring during an exposure phase than simple
averaging of CR scores. An apparent methodological differ-
ence to previous work was the use of immediate extinction,
excluding potential effects of long-term fear memory
consolidation processes on CRs measured in extinction. It is
therefore possible that the extinction resistance observed by
Lonsdorf and co-workers
28 reﬂects better fear memory
consolidation in met/met-carriers rather than a deﬁcit in safety
learning. In this context, it is worth noting that DA has been
implicated in memory consolidation processes in animal
studies (for example, ref. 47).
Like the enhanced and persistent fear conditioning in low
5-HTT-expressing individuals, the putatively enhanced fear
memory consolidation in COMT met/met-carriers should be
associatedwith enhancedrisk forPTSD. Twoepidemiological
studies support this prediction. Kolassa and co-workers
48
observed that met/met-carriers, after experiencing at least
one traumatic event, had a high risk for lifetime PTSD. By
contrast, val-allele carriers showed the typical dose-depen-
dent increase of lifetime PTSD risk with increasing trauma
load. In analogy to the pattern observed with respect to
5-HTTLPR genotype, the ‘risk’ genotype (met/met) conferred
a higher lifetime PTSD risk in particular at lower trauma loads,
and differences between the genotype groups vanished at
high traumatic load (415 events), again suggesting that
the inﬂuence of genetics decreases with increasing trauma
load.Importantly,genotypegroupsdidnotdifferinthenumber
or types of traumatic events experienced, rendering a
gene–environment correlation (for example, exposure
to trauma may depend on the individual’s genotype),
49 rather
unlikely.
In a similar vein, Valente and co-workers
50 found a
signiﬁcantly higher frequency of the COMTval158met met-
allele in Brazilians who had developed PTSD after a single
urban trauma than in individuals resilient to PTSD and in a
community sample. Further, trauma-exposed individuals
carrying a met-allele reported signiﬁcantly more PTSD
symptom severity than non-carriers. Limitations of this study
include the rather small sample sizes for trauma exposed
individuals (N¼99, whereof 34 resistant to PTSD) and
different genotype and allele frequencies in the three groups.
As trauma exposure was not assessed in the community
sample and different allele frequencies were observed in
the different groups, a gene–environment correlation cannot
be ﬁnally excluded.
Insum,thecurrentliteraturepointstowardanimportantrole
for COMTval158met in fearmemory consolidation, which also
affects extinction success once sufﬁcient time for consolida-
tion of the fear memory has elapsed. Because exposure
therapy occurs with a considerable delay to trauma, COMT-
val158met genotype might turn out as a predictor of treatment
response.
DAT1 VNTR (rs28363170). The DAT mediates DA reuptake
and thus regulates the duration and amplitude of DAergic
signaling, particularly in striatal areas.
51 The DAT1 gene
harbors a 40bp-VNTR polymorphism in its 30-untranslated
region that most frequently occurs as 9 or 10 tandem
repeats (R).
Of those studies ﬁnding VNTR effects on DAT expression,
cell-based assays majorily indicate that the 9R-allele reduces
expression,
52–54 whereas evidence from human studies
is split.
55–58 According to current models, reduced DAT
expression should amplify phasic DA signals.
51
In their above sample, Raczka and co-workers
46 used
formal computational modeling (see above) to show higher
learning rates during extinction (but not conditioning) in DAT1
9R-carriers as compared to non-carriers. Of note, standard
analyses comparing phase-averaged SCR and rating scores
showed no group differences. Higher learning rates were
accompaniedbyhigheractivation oftheventralstriatumtothe
unexpected UCS omission in extinction. In associative
learning theory, such ‘prediction errors’ are supposed to drive
association formation (here, betweentheCS and theabsence
of the UCS) and phasic ventral–striatal DA release iscurrently
the prime candidate for prediction error encoding in appetitive
conditioning.
59 Drawing an analogy between learning
to expect safety (in extinction) and learning to expect reward
(in appetitive conditioning), the authors suggested a contribu-
tion of the meso-striatal DA system to extinction learning.
No group differences in striatal prediction error encoding were
observed in the conditioning phase.
DRD2 C957T (rs6277). The synonymous SNP in the DRD2
gene, DRD2 C957T (rs6277), was initially assumed to be
functionally silent. Later, the T-allele was associated with
decreased mRNA stability and protein synthesis in vitro
60
and higher DRD2 receptor afﬁnity (C/CoC/ToT/T).
61
In a sample of 60 individuals, Huertas and co-workers
62
found T-carriers to display signiﬁcantly lower SCRs to CSþs
in one late compared with one early conditioning trial (see
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an increase. No differences between the genotype groups
were found in CS  and UCS SCRs. A formal test of SCR
discrimination (CSþ4CS ) was not reported. In extinction,
no differences between the genotype groups were found.
Limitations of the study include very unequal sample sizes
and the use of single trials (N¼1–3) for statistical analyses
(see Table 3).
DRD4R VNTR. The DRD4 gene contains a VNTR
polymorphism of a 48bp sequence that affects D4 receptor
function in vivo.
63 The 7R variant leads to decreased
inhibitory post-synaptic DA effects compared with the 4R
and the 2R forms.
64 Caucasians are mostly grouped as 7R
carriers vs non-carriers, but a new suggestion for functional
classiﬁcation has been proposed recently.
65,66
Garpenstand and co-workers
27 (see above) found no
DRD4R VNTR genotype variant (long: 6–8R vs short: 2–5R)
over-represented in good or poor conditioning performers.
Although no difference in SCRs were found during condition-
ing, long-allele carriers showed signiﬁcantly more CSþ/CS 
discrimination during extinction. However, this association did
not survive correction for multiple comparisons. In addition,
extinction results in this sample must be interpreted in the
awareness that participants were selected based on extreme
performance during conditioning (see above).
Brain-derived neurotrophic factor
BDNF val66met. Brain-derived neurotrophic factor (BDNF)
is the most abundant neutrophin in the central nervous
system and is implicated in synaptic plasticity.
67 The human
BDNF gene harbors a functional G/A SNP in its pro-domain,
leading to a valine to methionine substitution in codon 66
(BDNFval66met). The met-allele is associated with impair-
ments in intracellular trafﬁcking and activity-dependent
BDNF secretion.
68,69
Animal work has implicated BDNF in hippocampus-
70 and
amydala-dependent
71 learning and memory, and to date,
three human studies exist.
Hajcak and co-workers
72 used a fear generalization
paradigm in 57 participants. A rectangle served as CSþ,
and three different rectangles, differing gradually in size from
the CSþ, served as CS s (see Table 2 for details).
A signiﬁcant stimulus genotype interaction on FPS was
observed in the absence of differences in ITI startle reactivity,
chosen UCS (shock) intensity or UCS likelihood ratings.
Homozygous val-carriers showed signiﬁcantly higher FPS to
the CSþ than met-carriers, relative to the CS  that was
maximally dissimilar from the CSþ. No differences in FPS
to the various CS s were observed.
Similarly, Lonsdorf and co-workers
73 reported in a sample
of 48 individuals more pronounced FPS CSþ potentiation
and CSþ/CS  discrimination in val-carriers as compared to
non-carriers during late (but not early) conditioning. This
carried over to the early (but not late) extinction phase 24h
later, manifesting as signiﬁcantly more pronounced CSþ
potentiation in homozygous val-carriers. Because genotype
groups had reached similar fear reduction at the end of
extinction, this most likely reﬂects enhanced fear memory
retrieval, rather than a safety learning deﬁcit. No difference
was found in SCR discrimination. Both studies were limited by
unequal numbers in the two genotype groups (see Table 3).
Soliman and co-workers recently
74 published a paradigm
consisting of a conditioning, a reversal learning and an
extinction phase following immediately upon each other in a
sample that consisted of an equal number of met-carriers and
non-carriers (total N¼72). During reversal learning, the
stimulus that had served as CSþ during conditioning now
served as the CS  and vice versa, and in extinction,
both stimuli were unpaired (see Table 2 for details).
During fear conditioning, met-carriers showed an overall
heightened SCR to both CSþ and CS  in the absence of
group differences in SCR discrimination (CSþ4CS ).
Stronger CS  responses during late conditioning in met-
carriers than in val-homozygotes were interpreted as a deﬁcit
in safety learning. No SCR data from the subsequent reversal
phase were reported. During extinction, there were again
generally heightened SCRs in met-carriers. Speciﬁcally,
during late extinction, responses to the CSþ (¼CS  in
reversal) were higher in met-carriers. CSþ/CS  discrimina-
tion and CS  (¼CSþ in reversal) responses were not
reported. This and the unorthodox reversal manipulation
preceding the extinction phase (resulting in the CSþ already
being consistently presented unpaired with the UCS before
extinction) calls for further qualiﬁcation of the authors’
interpretation of the data as reﬂecting an extinction deﬁcit in
met-carriers. A concurrent ﬁnding of decreased brain activa-
tion during extinction in met-carriers in the ventromedial
prefrontal cortex and enhanced activation in the amygdala to
CSþs( ¼CS  in reversal) relative to a ﬁxation baseline
would also require further information about preceding
activations in conditioning and reversal, as well as responses
to CS  (¼CSþ in reversal) and CSþ vs CS  contrasts
to draw ﬁrm conclusions. So far, it cannot be excluded that
the results merely reﬂect the generally heightened CS
responsivity in met-carriers.
The picture that emanates from these three studies
is relatively inconsistent, the strongest overlap lying in
the enhanced FPS conditioning in val-homozygotes. In an
attempt to shed further light on potential BDNF genotype
effects, we reanalyzed SCR and fear rating data from a
previouslypublisheddatasetusingacontinuousconditioning–
extinction–reconditioning paradigm in 46 val-homozygotes vs
23 met-carriers
75 (see Supplementary Information). Homo-
yzgous val-carriers showed generally heightened SCRs to
both CSþs and CS s during reconditioning only, in the
absence of any group differences in discrimination. In fear
ratings, val-homozygotes showed less CSþ/CS  discrimina-
tion, caused by lower fear ratings to CSþs, relative to
met-carriers, in both conditioning and reconditioning. Learning
rates showed no genotype effects. Hence, these data rather
enhance the disagreements currently existing in the literature.
To sum up, no clear picture emerges currently from data on
the BDNFval66met genotype (for differences in design and
methods see Tables 1 and 2) and results must be treated
preliminary until replicated by independent laboratories.
As animal studies have implicated BDNF in hippocampus-
dependent learning and human studies have shown
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processes,
69 context conditioning, relying heavily on the
hippocampus, may be a more promising candidate for future
studies.
Other systems
ANKK1 Taq1A (rs1800497). The novel ankyrin repeat and
kinase domain containing (ANKK1) gene is involved in
signal-transduction pathways
76 and harbors the Taq1A
restriction fragment length polymorphism (Glu713Lys). The
polymorphism was initially thought to be located within the
nearby DRD2 gene, but from the current state of knowledge,
its initial association with altered D2 receptor density
77,78
is problematic.
Huertas and co-workers
79 (see above) found no associa-
tion of the ANKK1 Taq1A restriction fragment length
polymorphism with fear learning and (immediate) extinction.
As for the authors’ analysis of DRD2 C957T in the same data
set, unequal group sizes and the use of single trials for
statistics (see above and Table 3) have to be mentioned as a
limitation.
NPSR1 Asn
107Ile (rs324981). Neuropeptide S (NPS) is a
recently discovered neuropeptide that animal studies have
implicated in arousal, anxiety and fear learning (for a review,
see ref. 80). The human NPS receptor gene NPSR1 harbors
a functional A/T SNP, leading to an amino-acid exchange
from aspargine to isoleucine (Asn
107Ile). The T-allele is
associated with increased NPSR cell surface expression and
10-fold enhanced efﬁcacy of NPS at NPSR in vitro.
81,82
Raczkaandco-workers
75(seeabove)performedcondition-
ing, immediate extinction and immediate reconditioning in
66 healthy male volunteers. SCR results during the three
phasesrevealednogenotypegroupdifferencesinCSþ/CS 
discrimination or general CS responsivity. By contrast,
T-allele carriers gave higher CR ratings to both CSþs and
CS s during conditioning (reappearing at trend level in
reconditioning), suggesting that they may consciously over-
perceive or over-interpret their conditioned responses. This
was accompanied by CSþ hyper-responsivity of an area in
thedorsal–medialprefrontalcortexpreviouslyassociatedwith
conscious threat appraisal.
16
Paralleling these results, Domschke and co-workers
83
showed in 205 PD patients with agoraphobia that T-allele
carriers report signiﬁcantly stronger increases in perceived
symptomintensity elicited bya panic-relevant stimulus (sitting
in a small locked dark chamber) again in the absence of a
corresponding genotype effect on physiological responding
(heart rate).
Hence, there is converging evidence from two studies that
the T-allele of the NPSR1 Asn
107Ile SNP may be associated
with ampliﬁed subjective experience and interpretation of
fear reactions or stimuli, in the sense of catastrophizing
over-interpretations, which is thought to be crucial for the
development and maintenance of PD.
84,85 However, whether
thisSNPisalsoassociatedwithdisease-relevantfearlearning
and/or extinction processes remains an open question.
ADCYAP1R1 C/C (rs2267735). The pituitary adenylate
cyclase-activating protein (PACAP) stimulates cAMP
production in the anterior pituitary
86 and exerts pleiotropic
functions in development, metabolism and cell signaling (cf.
ref. 87).
Ressler and co-workers
87 identiﬁed the C/C genotype of an
SNP in the ADCYAP1R1 gene to be associated with PTSD in
female, but not male, highly traumatized urban civilian
subjects using a tag-SNP approach. In a sample of PTSD
patients (see Table 3), they also observed an association
between the C/C genotype and impaired CSþ/CS  startle
discrimination during late conditioning, again restricted to
females. Separate analyses for CSþ,C S   and ITI startle
responseswerenotreported,andthusitremainsunclearasto
whether the effect was due to impaired excitatory (less CSþ
responding) or inhibitory (too much CS  responding) learn-
ing. In support of ampliﬁed excitatory responding, females
with the C/C genotype also showed signiﬁcantly increased
dark-enhanced startle than non-carrier females, whereas
again no differences were found in males.
In sum, there is new promising evidence for a possible
association of an ADCYAP1R1 SNP with fear learning.
Summary
In our summary of genetic association studies on human fear
learning- and extinction-related processes, as well as their
clinical translations, two sets of ﬁndings clearly stand out.
First, there is now strong evidence (six positive reports
(PR)) that genetic variation in the 5-HTT gene affects
conditionability, in the sense of facilitated and possibly more
persistent fear conditioning in individuals with putative low
5-HTT expression (5-HTTLPR s-allele or LG-carriers), and
that these individuals are also characterized by vulnerability
to PTSD after trauma and possibly more severe clinical
symptom proﬁles.
Second, there is good evidence (4PR, 1 negative report)
that genetic variation in the COMT gene affects fear memory
consolidation,inthesenseofstrongerandextinction-resistant
fear memories in met-allele carriers, as well as associated
increases in the risk for PTSD after trauma as well as
resistance to exposure-based treatment in PD patients.
The work on 5-HTTLPR and COMTval158met draws an
impressive linebetweenpharmacological workin vitro,animal
models, human molecular genetics, behavioral genetics and
clinical studies and support the validity of the molecular–
genetic association study approach.
The available literature on the BDNFval66met genotype
and conditioning- and extinction-related processes is paved
bycontradictoryandunclearﬁndings,andrequires,givenhigh
clinical interest and promising animal work, further systematic
studies in humans.
Other observations of high potential interest, which how-
everrequirefurtherconﬁrmationandmechanisticclariﬁcation,
concern associations of genetic variants in the DAT1 gene
(1 PR) in extinction and of the ADCYAP1R1 gene (1PR) in
conditioning infemales. Inaddition, there isweak evidencefor
associations with the DRD2 C957T polymorphism (1PR)
and the DRD4 VNTR (1PR), whereas single negative
results were reported for the MAO-A VNTR, ANKK1 Taq1A
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Asn
107Ile SNP.
Translation of experimental ﬁndings into the clinical context
isimportantandgeneticassociationstudiesontheoutcomeof
CBT were found for the (triallelic) 5-HTTLPR (1PR in PTSD,
1 negative report in PD) and the COMTval158met polymorph-
ism (1PR in PD), and both are also associated with the
PTSD development after single or multiple traumata (2PR),
whereasexperimentalexposure hasbeen associatedwiththe
NPSR1 Asn
107Ile polymorphism (1PR).
Studying conditioning: methodological aspects. Where
necessary for an informed interpretation of the results, we have
addressed choices of outcome measures, data reporting
and study design, which, like many other methodological
aspects (data preprocessing, data reduction, scoring, statistical
analysis), differed considerably between studies (see also
Table 3). Methodological variation is inevitable because every
study is optimized for the speciﬁc question it is supposed to
answer. Nevertheless, observance of some critical rules might
help increase comparability between studies.
Perhaps most importantly, a formal statistical comparison
of outcome scores between groups is an absolute require-
ment for inferring genotype effects, whereas relying solely on
separate analyses for each different group is not informative.
Of similar importance is the decision which scores to report.
Speciﬁcally, in differential conditioning experiments, CSþ/
CS  contrasts as well as separate reporting of CSþ and
CS  responses can provide valuable information about
excitatory (CSþ) and inhibitory (CS ) mechanisms, as well
as general reactivity and sensitization effects. In this context,
it is helpful to be aware that different indicators of fear learning
tap slightly different processes and involve different neuro-
biological pathways, which is important for their interpretation.
For instance, FPS, in contrast to SCR, is not only sensitive to
the arousing properties of a stimulus but also to its valence, in
that it is speciﬁcally potentiated by unpleasant or aversive
stimuli
88 and inhibited by positive stimuli.
89 Furthermore, FPS
facilitates translation of results from animal to human work
given the well-delineated neural pathway involved in startle
potentiation and the similar measurements employable in
both species.
88 In this context, positive results in FPS in
combination with negative results in SCR in several of the
reviewed studies stick out. In addition to physiological indices,
self-report measures (fear or shock expectancy ratings) can
beinformative,inparticularasamanipulationcheckorincase
subjective experience is of speciﬁc interest. However, their
subjective nature renders them inherently vulnerable to
experimenter demand and it may thus be important to provide
accompanying information about a possible genotype inﬂu-
ence on tendencies for reporting in a socially desirable
manner (for example, quantiﬁed using appropriate question-
naires; ref. 90). In addition, the sharpening of contingency
awareness that is induced by such ratings needs to be traded
against the gain of information. We would also contend that
data reporting should ideally include all experimental phases.
For example, when solely interested in extinction, results from
the conditioning phase (or any preceding phase) need to be
reported in the same measurement modality to rule out pre-
existing group differences. Finally, we would like to draw the
reader’s attention to useful guidelines for psychophysiological
data recording and analysis (http://www.sprweb.org/journal/
index.cfm#guidelines).
A more speciﬁc issue is whether extinction should be
conducted immediately following the conditioning phase or
after a delay (for example, 24h). Animal work has suggested
thata distinction betweenimmediate anddelayed extinction is
critical, as only the latter may involve inhibition processes.
Immediate extinction may in turn lead to an erasure of the
learned responses,
91 although mixed evidence has emerged
lately from human research.
92,93 Critically, human studies
mostly apply immediate extinction, whereas extinction com-
monly does not occur immediately after conditioning in animal
studies or natural contexts, posing problems for translation of
ﬁndings.
This brief and non-exhaustive discussion of what might
appear to be small methodological details, which yet can have
strong bearing on results, highlights the need for a detailed
and comprehensive reporting of experimental procedures.
Tables 2 and 3 have been included in an effort to enable
the reader to draw his/her own conclusions, to facilitate
comparisons and to provide an initial basis for the planning of
future studies.
The association approach: limitations and
suggestions. Notwithstanding the apparent successes of
the genetic approach to human fear conditioning, some
important limitations should be kept in mind when interpreting
the results. The strongest limitation lies in the inherently
correlative nature of association studies, precluding
conclusions about causality. This is a particular concern
when chance co-variation of a polymorphism with other
potentially causal factors (other genetic variants, personality
characteristics) can never be fully excluded or when no
heritability measurements are available yet. Enlargement
of sample sizes and reproduction in independent cohorts can
to some extent protect against such confounds. In this
context, it is worth noting that only four studies
27,37,75
reported negative results (for a particular polymorphism or
measure), but all also included positive results for other
polymorphisms
27,28,62 or measures.
75 Thus, to date, there is
no single publication reporting negative ﬁndings, raising
concerns about publication bias.
The need for replication studies is also highlighted by the
fact that genotyping mostly was performed a posteriori
(see Table 2). This often resulted in unequal genotype
distributions (reﬂecting population allele frequencies) and
multiple testing of identical samples. Therefore, replication
studies should ideally be carried out in independent
study populations. Generally, a prospective genotyping
approach where participants are selected based on genotype
and a priori hypotheses, and where genotype groups are
matched for potentially relevant characteristics (for example,
gender, ethnicity, socioeconomic status, personality mea-
sures), can be considered advantageous and provide more
statistical power. We would also like to draw the reader’s
attention to the recommendations of the ‘STrengthening
the REporting of Genetic Association studies (STREGA)
initiative’.
94
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in the ﬁeld of fear conditioning and extinction have tapped
only very basic processes. Future studies should include
more ﬁne-grained analyses of learning and extinction
processes, for example, by discriminating between extinc-
tion learning and extinction recall,
95 and by disentangling
sensitization, consolidation and retention effects from
true within-session learning effects. In particular, one major
characteristic of learning has so far has been neglected with
few exceptions:
46 change over time within an experimental
phase (that is, for instance, changes across the trials of a
conditioning phase). Instead, data were presented mostly as
the mean of all reactions per experimental phase separately
for the CSþ and CS , and the difference between both
means. Although this approach is by no means incorrect or
uninformative, it limits interpretation of the data by a loss of
resolution in time.
Ingeneral,thespeciﬁcityoftheﬁndingstofear-andanxiety-
relevant processes remains to be addressed. First, neuro-
transmitters have widespread pleiotrophic effects on biologi-
cal processes as well as behavior and disease. Thus, the
subtle changes in one bottleneck of the system induced by
functionalpolymorphismsinasinglegenecannotbeexpected
to be more speciﬁc than the systems’ general function. Thus,
wearenotsearchingfora‘geneforfearlearning’ora‘genefor
extinction’, but rather for modulators on the DNA level.
However, also these modulators (for example, polymorph-
isms) rarely induce highly speciﬁc functional effects and it
cannot be neglected that genetic polymorphisms are carried
by an individual from the very early stages of embryonic
existence, allowing the organism—in contrast to acute
pharmacological interventions—to adapt to, and compensate
for, small shifts in the functionality of a molecular system, both
within and between systems. Hence, group differences
associated with a polymorphism in transmitter system
A might theoretically also be related to compensatory
adaptations in transmitter system B. A related concern is that
functional effects that are observed in vitro do not necessarily
map one-to-one on in vivo functioning, due to possible
compensatory mechanisms.
Although studies have so far been relying on the study of
single polymorphism candidates or the study of multiple
‘unrelated’ polymorphisms in the same sample, ‘systemic
haplotypes’ are likely to provide interesting new information
and partly overcome this limitation. Combining functional
polymorphisms in critical bottlenecks of a single (transmitter)
system and a subsequent grouping of individuals based on
inferred functional status of the system may be a promising
approach for future studies. Studies on single gene or single
polymorphismassociationsmayalsogeneratehypothesesfor
subsequentpharmacological challengestudies, andtogether,
both may provide convergent evidence for the involvement of
a molecular pathway. In animals, an interesting alternative
approach to association studies are gene expression studies,
which give a better picture of the underlying biological
pathways and mechanisms than genetics.
96 Still, it remains
an unresolved challenge to identify gene expression patterns
associated with learning processes in speciﬁc regions of the
living human brain. Although human research so far mostly
reliesontoolslikegeneticassociationstudies,functionalbrain
imaging and pharmacological challenge tests to unravel the
neurobiology of fear learning and extinction, animal work,
where gene expression studies are easily feasible, can
provide priority candidate genes and blood biomarkers that
call to be tested in humans.
96 In this vein, a recent article by
Le-Niculescu and co-workers
96 provides a list of candidate
genes for anxiety disorders identiﬁed using a convergent
functional genomics approach, whereof very few (for exam-
ple,DRD2)havebeeninvestigatedwithrespecttohumanfear
conditioning and extinction or related clinical phenomena.
In sum, translational work employing a synergy between
molecular genetics, neuroimaging, psychophysiology,
psychopharmacology and, possibly also, neuroendocrinology
will be powerful in unraveling the neurobiology of fear learning
and extinction processes. Because a signiﬁcant proportion of
patients do not respond to or tolerate standard treatments,
such advances may ultimately open up perspectives for new
pharmacological interventions targeted at speciﬁc neurobio-
logical pathways or genes as they activate during speciﬁc
therapeutic learning and memory processes. Hence, combin-
ing pharmacological target-speciﬁcity with temporal process-
speciﬁcity in the administration regimen should allow us to
increasetheefﬁcacyofexistinglearning-basedtreatments,as
in pharmacological enhancement of CBT (as already seen for
D-cycloserine
97 and cortisol.
98 Although the study of CBT is
still in its infancy, and suffers from the absence of evidence
that CBT responsiveness is heritable, it holds big hopes
for better anxiety treatments in the future.
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